Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 40Lymphoma, Mantle-Cell 27Lymphoma 26Lymphoma, Follicular 25Lymphoma, Non-Hodgkin 23Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, B-Cell 14Lymphoma, B-Cell, Marginal Zone 13Burkitt Lymphoma 12Recurrence 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Waldenstrom Macroglobulinemia 6Leukemia, Hairy Cell 5Lymphoproliferative Disorders 4Leukemia 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3beta-Thalassemia 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Infections 2Hodgkin Disease 2Hematologic Neoplasms 2Epstein-Barr Virus Infections 2

Interventions

Rituximab 1Lenalidomide 1CT-P10 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Composite Lymphoma × Rituximab × 90 days × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡